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The human disease paroxysmal nocturnal hemoglobinuria (PNH)' may be
regarded as an experiment of nature that has already provided, and should
continue to provide, unique insights on the cytolytic function ofcomplement (C)
and its regulation (1-4). The studies of our laboratory have been focused
particularly on elucidating the process by which the most sensitive type of PNH
erythrocyte (E) (designated type III) are abnormally sensitive to in vitro reactive
lysis, i.e., to membrane attack initiated by purified C5b6, C7, C8, and C9 in the
absence ofthe earlier activation and amplification steps (5).
In an earlierreport (6), we presented evidence that foragiven input ofpurified
C5b6, type III PNH E (PNH-III E) did not bind '21I-C7 to a greater extent than
normal human E. Rather, thedata indicated that PNH E underwenttwo- fourfold
greater lysis for a given number ofC7 moleculesbound. Compatible results were
obtained in less extensive, unpublished studies with radiolabeled C5b6. Compel-
ling independent evidence from other laboratories (7) indicates that the basic
unit of the membrane attack complex involves one molecule each of C5b, C6,
C7, and C8 in the formation ofthe C5b-8 complex, to which a variable number
of C9 molecules then bind to produce the fully effective membrane attack
complexes. Therefore, although C8 uptake has not been directly measured in
our system, it seemsjustified to infer that in reactive lysis the assembly of C5b-8
complexes on PNH-III E from the fluid phase is quantitatively normal. The
excessive lysis of the PNH E by the full C5b-9 sequence could result from a
quantitative abnormality affecting C9 binding and/or polymerization within the
C5b-9 complex, or from a qualitative difference in the disposition or function of
the terminal C components after they have become bound to the PNH mem-
brane. The previously reported deficiency of a membrane complement regula-
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tory protein, decay-accelerating factor (DAF), in type II and type III PNH E (3,
4) accounts for increased C3b binding to these cells during classical or alternative
pathway activation in whole serum, but does not appear to be involved in the
regulation of the susceptibility of E to reactive lysis (8, 9) .
In this report we compare the binding of 1251-C9 to type II and III PNH E
and normal E in reactive lysis, as well as in classical pathway-initiated lysis, with
attention to both total specific binding and the proportion of cell-bound C9 in
high molecular weight (HMW) forms. A preliminary account of these findings
has been presented (10).
Materials and Methods
Cells.
￿
Erythrocytes from two PNH patients with >95% type III E, one patient with
>90% type II E, and from normal controls, were obtained and stored frozen at -80'C
as described previously (5). PNHand normal E frozen for approximately equal times were
thawed on the same day, washed, and stored in Alsever's solution at 2°C until used
simultaneously in experiments (generally <2 wk after thawing) .
Complement Components.
￿
Human C5b6 was purified by a modification of the method
of Yamamoto and Gewurz (11) in which a C5/C6 reagent depleted of C7 was prepared
by pooling the C5- and C6-containing fractions from a DEAE Sephacel (Pharmacia Fine
Chemicals, Piscataway, NJ) column as described by Hammer et al. (12). Cleavage of C5
using serum-treated zymosan and subsequent purification of C5b6 were as reported (11).
Human C7 was prepared and radiolabeled as previously described (6). C9 was purified by
a combination of published methods. The C9-containing fractions from a DEAE Sephacel
column (12) were concentrated and applied to a 2.5 X 100 cm column of Sepharose 6B
(Pharmacia Fine Chemicals), which had been equilibrated in 25 mM barbital buffer, pH
7.0, containing 100 mM NaCl and 0.5 mM PMSF (13). The column was eluted with
starting buffer and the C9-containing fractions were pooled and applied to a 2.6 X 4.5
cm column of hydroxyl apatite (HA Ultrogel; LKB Instruments, Inc. Gaithersburg, MD),
which had been equilibrated in the buffer used for the preceding column . The column
was washed with starting buffer and then with 80 mM Na'/K' phosphate buffer, pH 7.7,
after which a 9-column volume linear gradient of 80-400 mM Na'/K' phosphate buffer,
pH 7.7, was applied. The C9-containing fractions were pooled and concentrated using a
PM30 membrane (Amicon Corp., Danvers, MA). Guinea pig C1 (14) and human C3, C6,
C8 (12), and C5 (15) were purified by published methods. Human C2 and C4 were
purchased from Cordis Laboratories Inc. (Miami, FL), and C2 was oxidized with 12 (16)
just before use.
Radiolabeling. The C9 preparations were radiolabeled with 1251 using the Iodogen
method (Pierce Chemical Co., Rockford, IL) at 0°C, according to the manufacturer's
instructions. After decanting from the Iodogen-coated tubes and quenching with cold
Nal, we added 1 mg/ml of human serum albumin (Sigma Chemical Co., St. Louis, MO).
Unbound 1251 wasremovedby overnight dialysis at 4°Cagainst phosphate buffered saline,
pH 7.5,containing 0.01 M EDTA, with Rexyn 201 beads(Fisher Scientific Co., Pittsburgh,
PA) added to the chamber. The final preparations containing 25 ug of radiolabeled C9
were absorbed twiceat 0°C with 1 .25 X 109 washed normal human E. This step removed
-18% of the radioactivity, and it reduced nonspecific C9 binding without significantly
changing the C9 hemolytic titer of the radiolabeled preparation. The final preparations
used for the binding experiments reported here contained 1.55-1 .96,uCi/tig C9 and the
radioactivity was 92-99% precipitated by 10% TCA. Some experiments were performed
with C9 radiolabeled by the lactoperoxidase method (Enzymobeads; Bio-Rad Laboratories,
Rockville Center, NY). These preparations did not require absorption with normal E.
Results using C9 radiolabeled by either method were comparable. The C9 concentration
of each radiolabeled preparation was measured by electroimmunoassay using specific anti-
C9 (Miles Laboratories, Elkhart, IN). The reference standard for C9 was a pool of 14
normal human sera, which was assumed to contain 58 tig C9/ml (13).ROSENFELD ET AL.
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The C9 preparations appeared homogeneous by Coomassie blue staining of SDS-PAGE
gradient gels. Using radiolabeled preparations, autoradiography of such gradient gels
with or without reducing conditions revealed that 91-97% of the radioactivity appeared
in the monomeric C9 band. For some experiments, the radiolabeled C9 was applied to a
column of Sephadex G-200 (Pharmacia Fine Chemicals) to remove any SDS-sensitive C9
aggregates formed during the radiolabeling procedure.
C9 Binding.
￿
Frozen E of PNH-III, PNH-II, and normal individuals were thawed on
the same day, washed in 5 mM barbital buffer, pH 6.5, containing 150 mM NaCl, 20 mM
EDTA and 0.1 % gelatin (GVBE6.5), and were standardized by electronic counting (Coulter
Electronics Inc., Hialeah, FL). 3.5 X 108 E of each type were pelleted and the supernatant
was removed. Excess C5b6 in GVBE6.5 was placed in each tube and the tubes were
incubated at 37°C for 10 min in a shaking water bath. Then, 230 ng C7 in the same
buffer were added (final volume, 140 pl), and the tubes were incubated another 10 min
at 37°C. The resulting EC5b67 were washed twice in 5 mM barbital buffer, pH 7 .4,
containing 150 mM NaCI, 20 mM EDTA, and 0.3% human serum albumin (HSA-VBE7.4),
were resuspended with 3.8 ml of the same buffer, and aliquots of these suspensions were
removed for cell counts. In a typical experiment, 3 X 107 EC5b67 ofeach cell type in 325
pl HSA-VBE were placed in a series of I I X 75-mm polycarbonate tubes. Duplicate sets
of tubes for each cell type received either of two dilutions of C8 (25 Al), buffer (HSA-
VBE7.4, 25 Al), or NH40H (to determine 100% lysis). 34 ng of radiolabeled C9 in 25 pl
HSA-VBE7.4 were added to each tube, and incubation proceeded for 60 min at 37°C;
then 2.5 ml of cold saline containing 0.09 M EDTA (pH 7.4) was added to each tube .
Unlysed cellsand ghosts were pelleted by centrifugation at 17,000 rpm for 10 min at 4°C
in a Sorvall RC-2B centrifuge with an SM24 head (Dupont Co., Wilmington, DE). The
supernatant was removed and released hemoglobin was determined by absorbance at 413
nm for the calculation of lysis. The pellet was washed sequentially in 60, 30, and 20
mosmol phosphate buffers, pH 7.5, with the ghosts recovered at each step by centrifuga-
tion at 17,000 rpm for 10 min at 4 °C. After the final 20 mosmol wash and removal of
the supernatant, the residual white ghosts were transferred quantitatively to fresh poly-
carbonate tubes by using four 0.5-ml aliquots of 20 mosmol buffer, and were recentri-
fuged. The supernatant was then removed with a measured aspirator leaving 100 pl in
each tube. 100 pl of double-strength SDS-PAGE sample buffer (see below) were added to
each tube and the tubes were placed in a boiling water bath for 1 .5 min. Two aliquots of
90 pl each were removed from each tube and counted for radioactivity; nonspecific counts
bound in the absence of C8 were subtracted from the total to obtain specific binding. The
molecules of C9 bound were calculated using the measured specific activity of the C9
preparation, assuming a molecular weight for C9 of 71,000 (13). Actual cell counts of the
EC5b67 suspension were used to calculate molecules of C9 bound per E.
In some experiments we used different cell numbers and volumes than those described
above. Other modifications included substituting 0.1 or 0.2% gelatin for 0 .3% HSA in
the buffer used in the C8 and C9 steps; substituting 5 mM Mg" and 1 .5 mM Ca21 for the
EDTA in this buffer; and performing the entire reactive lysis procedure in a single step,
wherein C5b6 was added to tubes containing E, C7, C8, and radiolabeled C9, either in
EDTA or in Ca2'- and Mgt'-containing buffers. Results with these modifications were
comparable to those obtained using the basic method described above.
C9 Binding During Classical Pathway-initiated Lysis.
￿
PNH and normal E (1 .2 X 108
cells/ml) were suspended in 2.5 mM barbital buffer, pH 7 .4, containing 75 mM NaCl, 5
MM MgC12, 1 .5 mM CaC12, 0.1% gelatin, and 0 .14 M sucrose (SGVB2+), and were
incubated for 20 min at 37 °C with an equal volume of SGVB21 containing appropriate
dilutions of heat-inactivated (56°C for 60 min) alloimmune human anti-Tja (5), guinea
pig Cl, and human C4. These EAC14 were washed in cold SGVB2+, resuspended to 1 .5
X 108 cells/ml, and incubated with excess C2 oxy, C3, C5, C6, and C7 in the same buffer
for 30 min at 37° . The resulting EACI-7 were washed in HSA-VBE7.4 and treated with
C8 and '25I-C9 as described above for EC5b-7 generated by reactive lysis. In some
experiments, washed EAC14 were incubated with a mixture of purified C2, C3, C5, C6,984 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
C7, C8, and varying doses of ' 25I-C9 in SGVBz+ for 60 min at 37°C, and then were
treated as above to determine lysis and C9 binding.
Polyacrylamide Gel Electrophoresis.
￿
Vertical slab PAGE was performed according to the
method of Laemmli (17) by using an SE600 apparatus (Hoefer Scientific Instruments,
San Francisco, CA). Linear gradients of 2.3-11 % polyacrylamide were poured using Gel
Bond-Pag supports (FMC Corp., Rockland, ME). Running buffers contained 0.1% SDS
(Bio-Rad Laboratories), and the sample buffers in which the ghosts were dissolved
contained either 0.1 or 2% SDS (final concentrations); 80 ul of each sample were applied
to the gel after radioactivity was counted. In some experiments we used 0 .5% SDS in the
sample buffer. Since 0.1 % SDS was the lowest concentration that consistently fully
solubilized all the membranes and allowed all of the radiolabeled C9 to enter the top of
the running gel, it was assumed that the HMW C9 complexes (see Results) identified with
0 .1 % SDS represented the maximum incorporation of C9 into cell-bound membrane
attack complexes detectable with an SDS-containing system. After electrophoresis the gels
were soaked in 7% acetic acid/5% glycerol solution, dried and subjected to autoradiog-
raphy at -80°C using Lightning-Plus Cronex intensifying screens (Dupont Co., Wilming-
ton, DE) and Kodak XAR-2 film (Eastman Kodak Co., Rochester, NY). The autoradi-
ograms were scanned using an ACD-18 Densitometer (Gelman Sciences, Inc., Ann Arbor,
MI).
Results
Reactive Lysis. Table I summarizes data from six different experiments in
which specific C9 binding to PNH E and normal E were compared, using the
basic reactive lysis system described in Materials and Methods and conditions in
which lysis is limited by CS concentration. Shown in Table I are the two most
commonly used inputs of C8. Similar comparative results were found with C8
inputs ranging from 6.5 to 99 ng/ml. Within a given experiment, lysis of PNH-
III E was 2.5-4.2 times that of normal E for patient L and 4.5-5.8 times that of
normal E for patient R. Nevertheless, the specific C9 bindingper PNH E is equal
to or less than that found for normal E. Therefore, the number of molecules of
C9 bound per effective lytic site is considerably lower for PNH-III E than for
normal E. The lysis of PNH-II E is only slightly greater than that of normal E
and the C9 binding is slightly less, so that somewhat fewer C9 molecules are
bound per lytic site by PNH-II E than by normal E.
Seven additional experiments using various modifications (see Materials and
Methods) of the above "C5b-8 limited" reactive lysis protocol yielded varying
absolute values for lysis and C9 binding, but the relationships between PNH and
normal E remained similar to those shown in Table I. To facilitate comparisons
between PNH and normal E throughout these 13 experiments, the data have
been normalized by dividing values for lysis (Z), C9 binding (molecules per E),
and C9 bound per lytic site (molecules per E per Z) obtained for PNH E by the
corresponding values obtained foreach normal Estudied in the same experiment.
The means (±SD) of the ratios representing each comparison are shown in Table
II . PNH-III E from patient R lysed 5.27-fold more than normal E in the 24
experiments with <100% lysis, whereas PNH-III E from patient L lysed 3.1
times normal, and the average lysis of PNH-II E was less than twice normal . The
C9 binding was equal to normal E for cells from patient R (type III) and from
patient K (type II), but only 58% of that found on normal E for cells from patient
L (type III). The last column in Table II presents the main finding, i.e., that
only 22-25% as many bound C9 molecules were required to producean effectiveTABLE I
C8-dependent Bindingof '251-C9 during Reactive Lysis of
Normal Human and PNH Erythrocytes
ROSENFELD ET AL.
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* Final concentration in reaction volume of 0.375 ml, containing 3 X 107 EC5b-7 and 91 ng/ml of 1251-C9.
Z = -ln(1 - fraction of cells lysed). This corresponds to effective lytic sites per cell if a single
complete C5b-9 site is assumedto be sufficient to lyse a cell.
§Specific binding is determined by subtracting cpm bound in the absence of C8 from total cpm
bound.
PNH-111 E(R)gave 100% lysis in 3 of 5experiments using 52 ng/ml C8, andin 1 of 5 experiments
using 13 ng/ml C8. Therefore, Z and C9 molecules per Z are calculated from only two values for
the higher C8 concentration and from four values for the lower C8 concentration. C9 molecules
per Ereflects all five experiments.
"Values are the means ± SD (where appropriate).
hemolytic site on either sample of PNH-III E as on normal E. PNH-II E are less
abnormal in this parameter.
Fig. 1 presents data from one offour C9 binding experimentsperformed with
constant C5b-8 but a broad range ofC9 inputs. All four experiments gave similar
results. At each C9 input used, lysis was greater for PNH-III E than for normal
E (Fig. 1 A), whereas specific C9 bindingwas similar for PNH and normal E (Fig.
1B). Lysis of PNH E was higher than for normal E at all levels of C9 binding
obtained (Fig. 1 C). Thus, lytic efficiency of bound C9 is higher on PNH-III than
on normal E when C9 is the limiting reagent, as it iswhen C5b-8 sitesare limiting
(Tables I and I1).
Next, we wished to determine whether specifically bound C9 was incorporated
into HMW C5b-8(C9) membrane attack complexes (MAC) with different effi-
ciency on PNH E than on normal E. Fig. 2 shows an autoradiogram of an SDS-
Erythrocyte
type
C8 input
(ng/m))*
Number
of experi-
ments
Lysis (Z)
Specific C9
Moleculesper E
bindings
Molecules per
effective lytic
site
PNH-111 (R) 52 51 3.05 333 ± 151' 138
13 5 2.45 ± 0.39' 160 ± 86 35 t 10'
PNH-111 (L) 52 5 2.39 ± 0.71 170 ± 47 77 ± 29
13 5 1.68±0.34 99±31 58±13
PNH-11 (K) 52 5 1.38 ± 0.15 345 ± 68 250 ± 51
13 6 0.71±0.14 154±70 215±84
Normal (A) 52 3 0.77 ± 0.15 427 ± 66 559 ± 96
13 4 0.45±0.13 227±69 516±53
Normal (B) 52 5 0.77 ± 0.27 363 t 88 535 ± 267
13 6 0.42 ±0.13 178 ± 71 485 ± 289
Normal (C) 52 5 0.96 ± 0.22 381 ± 147 429 ± 218
13 6 0.52±0.11 179±87 368±214
Normal (D) 52 1 0.62 147 236
13 1 0.27 100 366986 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
TABLE II
Summary Comparison ofPNH and Normal Erythrocytes in 13 Experiments:
Ratios of ValuesforReactive Lysis andSpecific C9 Binding
* See footnotes forTable I.
Data are means ± SD of ratios calculated by dividing values obtained for PNH E by corresponding
values for normal E in each of 13 experiments. The total numbers of comparisons in the 13
experiments areshown in parentheses. Data for lysis (Z) andC9 molecules bound pereffective lytic
site on type III PNH E (R) were compiled from fewer experiments than were available for
calculating C9 binding because these cells lysed completely in some experiments, so that Z values
could not be derived.
PAGE gradient slab (2 .4-11% acrylamide) loaded with ghosts (solubilized in
sample buffer containing 0.1 % SDS) from one of the reactive lysis experiments
summarized in Table 1. At a given C8 input PNH and normal E membranes
showed no obvious difference in the distribution of radiolabeled C9 among the
three main regions of interest : the polydisperse HMW region, disulfide-linked
dimer, and monomeric C9 . The reduced overall C9 binding to PNH-111 E of
patient L (Tables I and 11) is reflected in decreased radioactivity in all three
regions. The HMW C9 complexes found on ghosts solubilized in 0.1 % SDS also
contain C7 (data not shown), and presumably represent MAC bearing various
multiplicities of C9, accounting for their heterodisperse appearance in SDS-
PAGE. No C7 was found in the region occupied by C9 dimers.
The results of densitometric quantitation of the distribution of 1251-C9 radio-
activity in the autoradiogram shown in Fig. 2 are presented in Table 111. Lysis
and total unfractionated C9 binding for each cell type in this experiment are
shown for reference. As usual, total C9 binding on PNH E is equal to or less
than that seen on normal E, whereas lysis is greater for PNH E. Also shown is
the specific C9 binding in the HMW region of the autoradiogram, quantifying
the incorporation of C9 into MAC. The absolute amount of HMW C9 on PNH
E is similar to or less than that on normal E, and therefore, the number of HMW
C9 molecules per effective hemolytic site is considerably smaller for PNH-III E
than for normal E or PNH-11 E, indicating increased hemolytic efficiency of
MAC-associated C9 on PNH-III E. SDS-PAGE analysis of the experiments with
limiting C9 gave similar results, although the HMW and dimer C9 bands were
not visible on the autoradiographs of the tracks with the lowest C9 inputs, due
to lack of sufficient counts on the gels .
Washed ghosts bearing "'I-C9 were also dissolved in sample buffer containing
2% SDS (without reducing agent) before SDS-PAGE and autoradiography,
Under these conditions most of the HMW "'I-C9 complexes appeared to be
dissociated into smaller complexes, dimeric '251-C9, and monomeric 1251-C9.
However, in multiple experiments some 1251-C9 remained in a faint broad band
in the highest molecular weight region, despite prior incubation in 2% SDS at
Erythrocytes compared
with normal Lysis (Z)*
C8-dependent
Molecules perE
bindingof "5I-C9*
Moleculesper effec-
tive lytic site
Type III PNH (R) 5.27 ± 3.21 (24)$ 0.92 ± 0.23 (45) 0.25 ± 0.15 (24)$
Type III PNH (L) 3.10 ± 1.38 (46) 0.58 ± 0.25 (46) 0.22 ± 0.11 (46)
Type 11 PNH (K) 1.76 ± 0.57 (41) 1.01 ± 0.30 (41) 0.60 ± 0.19 (41)w 8001
d 1
600.
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E
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FIGURE 1 .
￿
C9 binding during reactive lysis of PNH-III E (patient R) (0) and normal E (A)
over a wide range ofC9 inputs. EC5b-7 (1.2 X 107), prepared from each cell type with identical
inputs of C5b6 and C7, were incubated (60 min, 37°C) with 1 jig/ml C8 and the indicated
concentrations of '25I-C9 in a final volume of 130wl.
100°C for 1 .5 min. These SDS-resistant very HMW C9 complexes were more
apparent on PNH-III E (Fig. 3, lanes 1 and 2) than on PNH-II E (lane 3) or
normal E (lane 4) in 9 of 13 experiments, although the difference was often
more subtle than that seen in Fig. 3. In four experiments, these complexes were
similar on PNH and normal E but in no experiment were these SDS-resistant
diffuse HMW C9 complexes shown in greater concentration on normal E than
on PNH E. A few experiments used 0.5% SDS as well as 2%; the results were
similar with both SDS concentrations.
In other experiments, the 2% SDS-resistant HMW C9 complexes appeared as
sharp bands in the HMW region (mol wt ^-800-1,000 X 103), without any988 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
FIGURE 2 . Autoradiogram showing the molecular weight distribution of 1251-C9 on the
membranes ofPNH and normal E after reactive lysis .The washed membranes of complement-
lysed and unlysed E were solubilized in sample buffer containing 0.1% SDS and analyzed by
2.4-11% acrylamide gradient slab SDS-PAGE . The C9 monomer, dimer, andHMW regions
were verified by reference to radiolabeled mol . wt . markers (IgM, IgG, BSA; not shown) . Each
cell type is represented by three lanes corresponding to the C8 input: lane 1, 52 ng/ml ; lane
2, 13 ng/ml ; lane 3, no C8 .
difference between PNH and normal E (Fig . 3, lanes 5 and 6) . Most of the C9
dose-response experiments showed this sharp band, which did not appear to vary
according to C9/C8 ratio . A few experiments with ' 251-C7 revealed a similar
appearance of HMW C7 after dissolution of ghosts in 2% SDS (Fig . 3, lane 7),
indicating incorporation ofC7 together with C9 into SDS-resistant HMW com-
plexes during C lysis of human E, in agreement with Podack and Tschopp (7).
In any case these sharp bands of HMW C9, when seen, did not distinguish
between PNH and normal E in reactive lysis experiments .
Antibody-initiated Lysis by CI-C9 .
￿
Having shown that C9 binding and incor-
poration into membrane-bound HMW complexes are, with the one exception
just noted using 2% SDS, quantitatively similar on PNH and normal E during
reactive lysis, we wished to study the same processes during classical pathway-
mediated lysis, wherein the C3-amplifying effect of DAF deficiency could be
expressed .
Table IV displays the lysis, C9 binding, and C9 incorporation into HMW
complexes from a representative classical pathway experiment comparing PNH-
III E and normal E . EACI-7 were prepared from both cell types with antibodyROSENFELD ET AL.
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TABLE III
Quantitation of C9 Incorporation into HMWComplexes on PNH and Normal Erythrocytes
during Reactive Lysis
Total specific C9
￿
Specific C9 binding in
binding
￿
HMW complexes*
See footnotes forTables Iand II.
* Estimation by densitometric scan of autoradiograph shown in Fig. 2, in which membranes were
solubilized in 0.1% SDS. The amount of radioactivity in the HMW region of each track in the
autoradiogram is calculated by multiplying the fraction of total area underthe relevant portion of
the densitometry tracing by total cpm applied to the track. Specific binding is determined by
subtracting HMWradioactivity of tracks representing EC5b-7 incubatedwith " I-C9 in theabsence
of C8.
$Values for lysis and total C9 binding are means of duplicatedeterminations.
and purified C1-C7, as described in Materials and Methods. In separate studies
(not shown), antibody uptake by PNH and normal E was similar as measured by
binding of radiolabeled human CIq. EC5b-7 were also prepared with C5b6 and
C7 as in previously described experiments. When EACI-7 and EC5b-7 interme-
diates were incubated with the same concentrations of C8 and radiolabeled C9,
marked differences in C9 binding to PNH-III E were seen with the two inter-
mediates. PNH EACI-7 bound 13-20-fold more C9 than did PNH EC5b-7 .
This was accompanied by a marked increase in HMW C9 on PNH EACI-7 . The
hemolytic efficiency of cell-bound C9 (and HMW C9) was markedly greater on
PNH E during reactive lysis than during antibody-initiated classical pathway lysis
in this and other experiments. In the experiment shown in Table IV, the minimal
C8-dependent dose response for lysis of EACI-7 suggests that another compo-
nent, possibly antibody, was limiting. If so, some E (both PNH and normal)
would not be susceptible to C9 binding and lysis, whereas superfluous C9
molecules could have been bound to the lysed EACI-7. Although this would
render the calculation of lytic efficiency for EAC1-7 less reliable, it does not alter
Erythrocyte type C8 input
(ng/ml) Lysis (Z)
Molecules
per E
Molecules
per effec-
tive lytic
site
Molecules
per E
Molecules
pereffec-
tive lytic
site
Type III PNH (R) 52 00 (100%)$ 381$ - 284
13 00(100%) 195 - 144
Type III PNH (L) 52 2.16 155 72 114 53
13 1.78 94 53 66 37
Type 11 PNH (K) 52 1.59 373 234 215 135
13 0.95 192 202 129 136
Normal (A) 52 0.94 435 463 209 222
13 0.61 227 372 87 143
Normal (B) 52 0.81 414 509 231 284
13 0.49 224 458 106 216
Normal (C) 52 0.99 460 467 240 244
13 0.59 225 380 132 224990 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
FIGURE 3 .
￿
Composite of autoradiograms from three experiments in which E membranes
were solubilized in sample buffer containing 2% SDS . Conditions for SDS-PAGE were
otherwise as in Fig. 2 . The mot . wt . markers (x 10-s) (arrows) designate the positions of
radiolabeled IgM, IgG and BSA in each set of gels . Lanes 1-4 are from one of the 1251-C9
bindingexperiments summarized in Table I, with 13 ng/ml C8 input . Lane 1, PNH-III E (R) ;
lane 2, PNH-III E (L); lane 3, PNH-II E (K) ; lane 4, normal E. Lanes 5 and 6 compare the
distribution of 12-11-C9 on PNH-III E (R) (lane 5) and normal E(lane 6) from another reactive
lysis experiment . For comparison, the position of 1251-C7 solubilized from PNH-III E mem-
branes in a third experiment is shown in lane 7 .
the important conclusion of these experiments: that C9 binding and incorpora-
tion into HMW complexes is markedly greater on PNH-III E than on normal E
during classical pathway lysis, in contrast to that seen with reactive lysis. These
relationships are dramatically illustrated by the autoradiogram shown in Fig . 4 .
These findings are not surprising in view of the markedly increasedC3b binding,
and consequently enhanced C3/C5 convertase formation, known to occur on
PNH E during classical pathway activation (1) . In other experiments on classical
pathway lysis using '251-C7 (not shown), excessive binding of C7 and incorpora-
tion into HMW complexes were also shown on PNH-III E as compared with
normal E.
In experiments using a wide range of C9 concentrations in classical pathway-
mediated lysis, C9 could be clearly shown to be limiting, thus allowing valid
comparisons of hemolytic efficiency of bound C9 between PNH and normal
EAC1-7 . A representative experiment is presented in Fig . 5. As in reactive lysis,
PNH-III E lyse to a greater extent than do normal E at each C9 input (Fig . 5A) .
In contrast to reactive lysis (Fig . 1), PNH-III E bind more C9 than do normal E
at each C9 input, and this difference grows as C9 input increases (Fig . 5B).
However, the lysis per C9 bound is similar for PNH and normal E over theROSENFELD ET AL.
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TABLE IV
Comparison of C9 Binding and Incorporation into High Molecular Weight Complexes on PNH
and Normal Erythrocytes by Classical Pathway vs. Reactive Lysis
Total specific C9
￿
Specific C9 binding in
binding
￿
HMW complexes*
* EAC1-7 were generated by incubating type III PNH(R) or normal E with heat-inactivated human
anti-Tja, purified guinea pigC1, human C4,andhuman C2-C7 (see MaterialsandMethods). EC5b-
7 were generated with C5b6 and C7 . Washed EAC1-7 or EC5b-7 (1 .1 X 107/ml) were incubated
(60 min, 37°C) with the indicated concentrations of C8 (for buffer alone for nonspecific binding)
and '251-C9 (139 ng/ml).
$ See footnotes for Table III. The ghosts applied to the gel used for this autoradiogram were
solubilized in 0. I% SDS.
limited range of C9 binding achieved on normal E (Fig. 5C). Note the marked
difference in the scale of C9 binding between Fig. 1 (reactive lysis) and Fig. 5
(classical pathway lysis).
Discussion
We have adapted a system for reactive lysis (18, 19), using purified human
C5b6, C7, C8, and C9, that produces significant lysis of normal human E. With
this system, we have previously shown that PNH-III E lyse 3-5-fold more than
normal E at a given C input (5), and that this enhanced lysis is not accompanied
by increased C7 binding (6). In this report, we extend the observations with this
reactive lysis system to show that the enhanced lysis of PNH-III E is not
accompanied by increased C9 binding (Tables 1-III), or by overall increased
incorporation ofC9 into HMW membrane-bound complexes (Table III and Fig.
1), suggesting that cell-bound MAC-incorporated C9 is more efficient in produc-
ing lysis of PNH-III E than of normal E. There is a suggestion of a qualitative
difference in the cell-bound MAC on PNH-111 E, however. Our frequent (but
not universal) finding ofgreaterSDS-resistance ofHMWC9 complexes on PNH-
III E than on normal or PNH-1I E (Fig. 3) may reflect the presence of a lytically
relevant subset of C5b-9 complexes that are stabilized by interaction with
membrane lipids. The apparent HMW of these complexes could reflect high C9
multiplicity, or they could representSDS-resistant micelles containing membrane
constituents as well asone or more MAC. The capacity ofour current techniques
Cell intermediate
tested*
C8 input
(ng/ml) Lysis (Z)
Molecules
per E
Molecules
per effec-
tive lytic
site
Molecules
per E
Molecules
per effec-
tive lytic
site
PNH EAC1-7 34 2.81 2,910 1,035 1,795 638
PNH EAC1-7 17 2.64 2,827 1,052 1,818 676
Normal EAC1-7 34 0.72 374 521 253 352
Normal EAC1-7 17 0.71 314 442 238 335
PNH EC5b-7 34 00(100%) 230 - 202 -
PNH EC5b-7 17 1.59 136 86 129 81
Normal EC5b-7 34 0.69 240 349 200 291
Normal EC5b-7 17 0.48 144 300 109 227992 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
FIGURE 4 .
￿
Autoradiogram of SDS-PAGE analysis of E membranes from the experiment
shown in Table IV . Technical conditions were as described in the legend ofFig. 2, using0.1
SDS to solubilize the membranes . Each cell intermediate is represented by three lanes,
corresponding to CS input; lane 1, 34 ng/ml ; lane 2, 17 ng/ml; lane 3, no C8 . The positions
of the mol . wt . (x 10-s ) markers (radiolabeled IgM, IgG and BSA) are shown .
to resolve and identify these complexes may be borderline, but they are seen in
a majority of our experiments . In preliminary work using membranes from
complement-lysed PNH and normal E (separated from the unlysed E), these
HMW SDS-resistant C9 complexes were seen on normal E as well as on PNH E.
Our current techniques for separating lysed from unlysed E are insufficiently
quantitative to allow us to determine whether these SDS-resistant C9 complexes
are present in equivalent amounts on the lysed fractions ofPNHand normal E
in these experiments, but we are continuing work in this area . Nevertheless,
these observations raise the possibility that theHMW C9 complexes resistant to
dissociation by 2% SDS may represent the truly lytic configuration of bound
C5b-9, and that this configuration may be favored by the PNH-III E membrane .
We have studied two PNH patients whose blood contains >95% type IIIE (in
multiple blood samples from each patient), revealing interesting similarities and
differences between these examples of type III E. E from patient R consistently
lyse to a greater extent than those from patient L, and show greater C9 binding
(Table I) . E from patient L, while far more lytically sensitive than normal E or
PNH-II E, consistently exhibit lower C9 binding than normal E. When compared
with normal E, however, the lytic efficiency ofC9 on both examples ofPNH-III
is very similar (Table II) . These observations of consistent differences between
two PNH-III E populations raise the possibility that two mechanismsmay regulate2.5
N
" 2 . 0
N
N 1 .5
Y .
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FIGURE 5.
￿
C9 binding during antibody-initiated lysis by C1-C9 ofPNH-III E (*) andnormal
E(A) over a wide range of C9 inputs . EAC14were prepared from each cell type with identical
inputs of human anti-Tja, guinea pig C1 and human C4, and adjusted to 1.5 X 10 8/ml in
SGVB". 80 gl of cell suspension were mixed with 25 ;al of a mixture containing purified
human C2, 3, 5, 6, 7, and 8 plus 25 jAl of dilutions of `251-C9 in SGVB2+ , producing the final
C9 concentrations shown . After 60 min incubation at 37° , lysis and C9 binding were
determined as in Materials and Methods . Nonspecific binding in the absence of C2-8 was
subtracted from total binding .
the susceptibility ofnormal human E to lysis by human complement MAC: one
modulating C9 binding to EC5b-8, and the other modulating the ability of C5b-
9 to produce membrane lesions sufficient to lyse the cell . The latter mechanism
might act to limit membrane insertion of MAC, to enhance closure of the
channels formed by MAC, or to confer greater resistance to lysis by a given
number of channels . PNH patients R and L may represent variations within the
normal spectrum of C9 binding regulation, yet both are abnormal in their
sensitivity to the lytic effect ofboundMAC, suggesting that the latter abnormality994 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
is dominant in its effect on overall susceptibility to complement lysis. Confirma-
tion of these speculations will require further study.
In contrast, when antibody-sensitized Eare lysed by classical pathwayactivation
ofpurified C components, PNH-111 E bind far more C9 (and C7) than do normal
E. Much of this excess G9, however, is in a lytically less efficient form, so that
the overall lytic efficiency of specifically bound C9 on PNH-111 E is similar to
(Fig. 5) or less than (Table IV) that on normal E.
We have also studied one patient (K) whose blood contains >90% PNH-11 E.
Because of overlap between type II and normal E in the complement lysis
sensitivity test, this patient's blood could contain as many as 10% normal (type
I) E without being detected by this test, but the lysis curves suggest that few or
none of this patient's E are type 111. Although we originally believed that this
patient's type 11 E were normally sensitive to reactive lysis (5), our more extensive
subsequent experiments have shown modestly increased sensitivity to reactive
lysis of this patient's type II E. This is accompanied by normal C9 binding and
modestly enhanced lytic efficiency of membrane-bound C9, suggesting that the
PNH-11 E of this donor may share the same defect as PNH-111 E, but to a much
lesser extent, or that our patient has some type III E not detected by the
complement lysis sensitivity test.
Others have studied C7, C8, and C9 binding to PNH and normal E in different
lytic systems, obtaining results that differ in some respects from ours. Parker et
al . (20) studied lysis in C7-, C8-, or C9-depleted serum reconstituted with the
appropriate radiolabeled complement protein, but they did not measure C9 (or
other C component) incorporation into HMW complexes. When antibody-
sensitized E (EA) were lysed in such reconstituted serum, the findings of Parker
et al . resembled our own results with EA and purified C1-9 (Figs. 4 and 5), in
that they saw increased C9 (and C8) binding to PNH-111 EA at any given serum
concentration. These workers found increased lysis of PNH EA for any observed
quantity of C9 bound, whereas we found similar levels of lysis of PNH and
normal EA per C9 bound during classical pathway-initiated lysis using purified
C components with limiting C9 (Fig. 5 C). A more substantial difference between
our results was seen when Parker et al . studied lysis of unsensitized E in EDTA-
treated serum initiated by a fluid phase alternative pathway activator (cobra
venom factor-Bb complex), which the authors equated with reactive lysis. In
these experiments, PNH-111 E bound large amounts of C7, C8, and C9, and
lysed fully, whereas normal E bound undetectable amounts of C7, C8, and C9,
and did not lyse; PNH-111 E bound a somewhat greater number of C3 fragments
than did normal E. Many methodological differences exist between the studies
of Parker et al. and ours, but we cannot account for the striking differences
between their results and our C5b6-initiated reactive lysis experiments by: (a)
the method of radiolabeling C9; (b) the buffers used for the experiments; (c) the
presence of C5b6, C7, C8, and C9 in the reaction mixture simultaneously; or (d)
the method used to separate ghosts and E from unbound C9. We have attempted
to reproduce all of the above conditions used by Parker et al . (20) with our
purified components, and we still obtain similar C9 binding to PNH and normal
E. Ourabilityto recover PNH Eghosts bearing very high amounts ofradiolabeled
C9 in the classical pathway experiments indicates that our standard method ofROSENFELD ET AL.
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washing and recovering ghosts does not selectively lose PNH E ghosts bearing
excess radiolabeled C9. Preliminary experiments suggest that the presence of
reactive lysis inhibitors (lipoproteins and/or S protein) in the serum used in their
experiments may, at least partially, account for the differences between our
results and those of Parker et al. This is an area of ongoing investigation in our
laboratory. It does seem quite clear that CVF-Bb-initiated lysis in whole serum
is not equivalent to C5b6-initiated reactive lysis.
Hu and Nicholson-Weller (21), using a very different method of determining
C9 binding, have recently found a single sample ofPNH E to bind more C9 than
normal E (but equal C7 and C8). Most of their experiments were done with
antibody-sensitized E and whole serum, and these results are similar to ours using
classical pathway lysis (except that they found equal C7 binding on PNH and
normal E). In a single experiment using purified C5 through C9 activated by
acid exposure, Hu and Nicholson-Weller found 5-6-fold more C9 bound to
PNH than to normal E. They also reported finding more SDS-resistant poly-
merized C9 on PNH E, but equal efficiency of C9 insertion on PNH and normal
E; however, their report does not state whether this experiment was done with
classical antibody-serum treatment or with acid-activated purified C5-C9. If the
classical pathway of complement was used for the latter two experiments, their
results are consistent with ours, since we find increased C9 binding and C9
polymerization, but normal or decreased lytic efficiency of bound C9 on PNH-
III E by this mechanism. We cannot fully account for the other differences
between their results and ours, but the experimental systems used are very
different.
Although it seems clear that we and others do find markedly increased C9
binding to PNH-III E by some lytic mechanisms, it is equally clear from our very
reproducible findings with reactive lysis initiated by purified C5b6 that PNH-III
E can show markedly greater lysis than normal E withequal (oreven less) specific
C9 binding. Thus, there presumably exist some control mechanism(s) on normal
human E that can restrict lysis without restricting the amounts of C7 or C9
bound, and these mechanism(s) appear to be deficienton PNH-111 E. It is possible
that other mechanisms, perhaps interacting with control proteins of serum, may
limit C7 and C9 binding to human E, but these alone cannot account for the
enhanced sensitivity to reactive lysis of PNH-III E.
Summary
As part of a broader analysis of the mechanism(s) by which the most sensitive
(type 111) paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes are exces-
sively sensitive to reactive lysis by isolated C5b6, C7, C8, and C9, we have
compared type III PNH (PNH-III) and normal human E in respect to both total
specific binding of "5I-C9 and the proportion of cell-bound C9 appearing in
high molecular weight (HMW) complexes. In a previous report, we found that
after exposure to purified C5b6 and "5I-C7, specific C7 binding and, by impli-
cation, EC5b-7 formation were equal for PNH-111 Eandnormal E. In thepresent
study, C8-dependent binding of '25I-C9 to PNH-III EC5b-7 and normal EC5b-7
was also similar, although lysis of the PNH-III E was up to five times greater;
that is, PNH-III E required fewer bound C9 molecules to produce an effective996 C-9 BINDING TO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELLS
lytic site than did normal E. To quantify radioactivity in monomeric and HMW
forms of membrane-bound C9, lysed and unlysed E were subjected to low ionic
strength buffers to convert all E to ghosts. These ghosts were solubilized in 0.1
or 2% SDS (without reduction) and electrophoresed on 2.4-11 % polyacrylamide
gradient gels followed by autoradiography and densitometric scanning. With
0.1% SDS, broad, heterodisperse zones of HMWC9 were recovered from both
PNH and normal ghosts; the amounts of C9 incorporated into the HMW
complexes were similar for PNH-111 E and normal E. In selected experiments,
1251-C7 could be shown in these same HMW bands. When membranes were
solubilized in 2% SDS, the overall proportion ofHMWC9 complexes compared
with dimer and monomer C9 was reducedon both PNH and normal membranes.
In many, but not all experiments, more of the highest mol wt C9 complexes
were detected from PNH-111 E membranes solubilized in 2% SDS than from
normal or PNH-I1 E membranes similarly treated.
When antibody-sensitized E were lysed by purified C1-C9, PNH-III EA bound
far more C9than did normal EA, and both lysisand C9 incorporation into HMW
complexes were markedly and proportionately increased over normal; however,
lytic efficiency of1251-C9 bound to PNH EA was equal to or less than that bound
to normal EA.
These observations indicate that the exaggerated sensitivity of PNH-III E to
the isolated membrane attack sequence (C5b-9) does not require supranormal
C9 binding; nor was preferential formation ofHMW forms of C9 (i.e., as poly-
C9 or C5b-9 complexes) detected on PNH E when 0.1% SDS was used to
solubilize the membranes. The lytic differences between these cell types could
still involve differing efficiency in formation on the PNH E membrane of a
subset of especially lytically effective C5b-9 complexes, or might involve differ-
ences in membrane-damagingevents subsequent to C5b-9 assembly. The putative
highly lytic subset of C5b-9 complexes, or the subset of membrane-bound C5b-
9 complexes actually inserted in the lipid bilayer, might be those detected in
some experiments as the HMWcomplexes with greater resistance to 2% SDS.
We thank Irene Bayer, Donna Phipps, and Kevin Skerrett for excellent technical assist-
ance, and Penny Powers for skilled preparation ofthe typescript.
Receivedfor publication 7 May 1986.
References
1 . Rosse, W. F., and C. J. Parker. 1985. Paroxysmal nocturnal haemoglobinuria. Clin.
Haematol. 14:105.
2. Pangburn, M . K ., R. D. Schreiber, J. S. Trombold, and H. J. Muller-Eberhard. 1983.
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the
abnormal erythrocytes. J. Exp. Med. 157:1971 .
3. Nicholson-Weller, A., J. P. March, S. 1 . Rosenfeld, and K. F. Austen. 1983. Affected
erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in
the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci.
USA. 80:5066 .
4. Pangburn, M. K., R. D. Schreiber, and H . J. Muller-Eberhard. 1983 . Deficiency ofROSENFELD ET AL.
￿
997
an erythrocyte membrane protein with complement regulatory activity in paroxysmal
nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. USA. 80:5430.
5. Packman, C. H ., S. 1. Rosenfeld, D. E. Jenkins, Jr., P. A. Thiem, and J. P. Leddy.
1979 . Complement lysis of human erythrocytes: differing susceptibility of two types
of paroxysmal nocturnal hemoglobinuria cells to C5b-9.J. Clin. Invest. 64:428.
6. Rosenfeld, S. I., D. E. Jenkins, Jr., and J. P. Leddy. 1985 . Enhanced reactive lysis of
paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve in-
creased C7 binding or cell-bound Cab. J. Immunol. 134:506.
7. Podack, E. R., andJ . Tschopp. 1984. Membrane attack by complement. Mol. Immunol.
21 :589.
8. Medof, M. E., V. Nussenzweig, T . Kinoshita, S. Hall, A. Gottlieb, R. Silber, W. F.
Rosse. 1985 . Nature of the PNH defect. Complement. 2:53 (Abstr.)
9. Shin, M., V. Hu, G. Hansch, A. Nicholson-Weller. 1986. Membrane factors respon-
sible for homologous species restriction of complement-mediated lysis: evidence for
a factor other than DAF operating at the stage of C8 and C9.J. Immunol. 136:1777.
10. Rosenfeld, S, L, Phipps, D, C ., Jenkins, D. E., Jr., and J. P. Leddy. 1985. C9 binding
and incorporation into high molecular weight complexes on normal and paroxysmal
nocturnal hemoglobinuria erythrocytes. Fed. Proc. 44:551 . (Abstr.)
11 . Yamamoto, K., and H. Gewurz. 1978. The complex of C5b and C6 : isolation,
characterization, and identification of a modified form of C5b consisting of three
polypeptide chains. J. Immunol. 120:2088.
12. Hammer, C . H., G. H . Wirtz, L. Renfer, H . D. Gresham, and B. F. Jack. 1981 . Large
scale isolation of functionally active components of the human complement system.
J. Biol. Chem. 256 .
13. Biesecker, G., and H. J. Muller-Eberhard, 1980 . The ninth component of human
complement: purification and physicochemical characterization. J. Immunol. 124.
14. Nelson, R. A., Jr., J. Jensen, I. Gigli, and N. Tamura. 1966. Methods for the
separation, purification, and measurement of nine components of hemolytic comple-
ment in guinea-pig serum. Immunochemistry. 3:111 .
15. Nilsson, U . R., R. H. Tomar, and F. B . Taylor, Jr. 1972 . Additional studies on human
C5: development of a modified purification method and characterization of the
purified product by polyacrylamide gel electrophoresis. Immunochemistry. 9:709 .
16. Polley, M. J., and H. J. Muller-Eberhard. 1967. Enhancement of the lytic activity of
the second component of complement by oxidation.J. Exp. Med. 126:1013.
17. Laemmli, U . K. 1970. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature (Lond.). 227:680 .
18. Thompson, R. A., and P. J. Lachmann. 1970. Reactive lysis: the complement-
mediated lysis of unsensitized cells. I . The characterization of the indicator factor
and its identification as C7. J. Exp. Med. 131 :629.
19. Lachmann, P. J., and R. A. Thompson. 1970 . Reactive lysis: the complement-
mediated lysis of unsensitized cells. 11 . The characterization of activated reactor as
C56 and the participation of C8 and C9. J. Exp. Med. 131 :643.
20. Parker, C. J., T. Wiedmer, P. J . Sims, and W. F. Rosse. 1985. Characterization of
the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J.
Clin. Invest. 75:2074.
21 . Hu, V. W ., and A. Nicholson-Weller. 1985. Enhanced complement-mediated lysis of
type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9
binding and polymerization. Proc. Natl. Acad. Sci. USA. 82:5520.